Alembic Pharmaceuticals Limited
シンボルマーク: APLLTD.NS
NSE
990.3
INR今日の市場価格
33.3489
PER（株価収益率
0.6374
PEGレシオ
194.66B
MRK キャップ
- 0.01%
DIV利回り
Alembic Pharmaceuticals Limited (APLLTD-NS) 財務諸表
貸借対照表
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 921.2 | 610.9 | 2850.3 | |||||||||||||
balance-sheet.row.short-term-investments | 0 | 166.4 | 316.2 | 1869.7 | |||||||||||||
balance-sheet.row.net-receivables | 0 | 11291.1 | 11900.1 | 8067.3 | |||||||||||||
balance-sheet.row.inventory | 0 | 14752.7 | 16097 | 14861.5 | |||||||||||||
balance-sheet.row.other-current-assets | 0 | 2135.2 | -0.1 | -0.1 | |||||||||||||
balance-sheet.row.total-current-assets | 0 | 29100.2 | 28607.9 | 25779 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 29997.3 | 39472.6 | 36480.3 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 1548.2 | 3229.5 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 1548.2 | 3229.5 | |||||||||||||
balance-sheet.row.long-term-investments | 0 | 963.3 | 1184 | 493.1 | |||||||||||||
balance-sheet.row.tax-assets | 0 | 1230.1 | 58.8 | 1108 | |||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 537.4 | 348.8 | -0.1 | |||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 32728.1 | 42612.4 | 41310.8 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 0 | 61828.3 | 71220.3 | 67089.8 | |||||||||||||
balance-sheet.row.account-payables | 0 | 6798.1 | 7063.9 | 6687.7 | |||||||||||||
balance-sheet.row.short-term-debt | 0 | 6527.9 | 6449.7 | 3121.8 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 21.5 | |||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 692.3 | 721.4 | 2714.3 | |||||||||||||
Deferred Revenue Non Current | 0 | -831.4 | -1976.9 | 855.2 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 0 | 855.4 | -0.1 | 0.2 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1754.3 | 1679.5 | 3611.7 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 861.5 | 871.2 | 838.2 | |||||||||||||
balance-sheet.row.total-liab | 0 | 18123.6 | 18844.8 | 16420.1 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0 | 393.1 | 393.1 | 393.1 | |||||||||||||
balance-sheet.row.retained-earnings | 0 | 35684.4 | 25543.9 | 24241 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 335.4 | 18808.8 | 18513.8 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 7291.8 | 7629.7 | 8128.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 43704.7 | 52375.5 | 51276.1 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 61828.3 | 71220.3 | 67089.8 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | -606.4 | |||||||||||||
balance-sheet.row.total-equity | 0 | 43704.7 | 52375.5 | 50669.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||
Total Investments | 0 | 963.3 | 1184 | 493.1 | |||||||||||||
balance-sheet.row.total-debt | 0 | 7220.2 | 7171.1 | 5836.1 | |||||||||||||
balance-sheet.row.net-debt | 0 | 6465.4 | 6560.2 | 4855.5 |
キャッシュフロー計算書
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 3545.9 | 6201.1 | 13680.8 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 2754.3 | 2867.8 | 1834.7 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.change-in-working-capital | 0 | -575.6 | -3673.4 | 2395.4 | |||||||||||||
cash-flows.row.account-receivables | 0 | -2228.8 | -4696.2 | 5109.3 | |||||||||||||
cash-flows.row.inventory | 0 | 1344.4 | -1235.5 | -2986.2 | |||||||||||||
cash-flows.row.account-payables | 0 | -281.7 | 366.7 | 452.7 | |||||||||||||
cash-flows.row.other-working-capital | 0 | 590.5 | 1891.6 | -180.4 | |||||||||||||
cash-flows.row.other-non-cash-items | 0 | 1514.9 | 128 | -3277.1 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -4434.1 | -4256.4 | -6595.1 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | 18.7 | 46.1 | -4.6 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -70 | -1392.9 | -1861 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | -18.7 | 1869.7 | 1861 | |||||||||||||
cash-flows.row.other-investing-activites | 0 | 28.2 | 13.8 | -1788.4 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4475.9 | -3719.7 | -8388.1 | |||||||||||||
cash-flows.row.debt-repayment | 0 | -2000 | -3000 | -3792.7 | |||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 7340.8 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | -1965.6 | -2751.9 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 0 | 1346 | 3578.4 | -9522.4 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -2619.6 | -2173.5 | -5974.3 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | -9.3 | |||||||||||||
cash-flows.row.net-change-in-cash | 0 | 143.9 | -369.7 | 262.2 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 754.8 | 610.9 | 980.6 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 610.9 | 980.6 | 718.4 | |||||||||||||
cash-flows.row.operating-cash-flow | 0 | 7239.5 | 5523.5 | 14633.8 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | -4434.1 | -4256.4 | -6595.1 | |||||||||||||
cash-flows.row.free-cash-flow | 0 | 2805.4 | 1267.1 | 8038.7 |
損益計算書の行
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 56526.2 | 52317.9 | 52762.2 | |||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 17088.2 | 17231.9 | 15212.7 | |||||||||||||
income-statement-row.row.gross-profit | 0 | 39438 | 35086 | 37549.5 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 0 | 27.4 | 1.3 | 2 | |||||||||||||
income-statement-row.row.operating-expenses | 0 | 35108.9 | 29160 | 24581.1 | |||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 52197.1 | 46391.9 | 39793.8 | |||||||||||||
income-statement-row.row.interest-income | 0 | 3.3 | 17.3 | 15.8 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 501.7 | 177.3 | 160.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -831.8 | 379.3 | 1029.8 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 27.4 | 1.3 | 2 | |||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -831.8 | 379.3 | 1029.8 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 501.7 | 177.3 | 160.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 2754.3 | 2867.8 | 1834.7 | |||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | 0 | 4377.8 | 5874.7 | 12968.4 | |||||||||||||
income-statement-row.row.income-before-tax | 0 | 3545.9 | 6201.1 | 13680.8 | |||||||||||||
income-statement-row.row.income-tax-expense | 0 | 126.1 | 1044.6 | 2533.2 | |||||||||||||
income-statement-row.row.net-income | 0 | 3419.9 | 5209.4 | 11465 |
よくある質問
Alembic Pharmaceuticals LimitedAPLLTD.NS 総資産とは何ですか？
Alembic Pharmaceuticals Limited (APLLTD.NS) 総資産は 61828300000.000.
企業の年間売上高とは？
年間収益は N/Aである.
企業の利益率は？
利益率は 0.711 である.
企業のフリーキャッシュフローとは？
フリーキャッシュフローは 28.216.
企業の純利益率は？
純利益率は 0.096 である.
企業の総収入は？
総収入は 0.100 である.
Alembic Pharmaceuticals Limited (APLLTD.NS) 純利益（純利益）とは何ですか？
純利益（純利益）は 3419900000.000.
負債総額は？
負債合計は 7220200000.000 である.
営業費用はいくらですか？
営業費用は 35108900000.000 である.
会社の現金はいくらですか？
企業の現金は 0.000 である.